Inhaled CBD before brain tumor implantation significantly reduced glioblastoma growth in mice
Mice pretreated with inhaled CBD for 14 days before glioblastoma implantation showed significantly reduced tumor burden, with lower expression of immune checkpoint and aggressive tumor markers.
Quick Facts
What This Study Found
Fourteen days of inhaled CBD pretreatment before tumor implantation significantly reduced glioblastoma burden compared to both placebo and 3-day CBD groups. The longer pretreatment was accompanied by decreased expression of IDO, PD-L1, MGMT, and Ki67, markers associated with immune evasion, treatment resistance, and tumor proliferation.
Key Numbers
Two pretreatment durations tested (3 and 14 days); 14-day CBD significantly reduced tumor burden; decreased IDO, PD-L1, MGMT, and Ki67 expression compared to placebo and 3-day groups
How They Did This
Preclinical study in C57BL/6 mice pretreated with inhaled CBD for either 3 or 14 days, or placebo, before intracranial implantation of glioblastoma cells. Tumor growth, immune checkpoint markers (IDO, PD-L1), and biomarkers (MGMT, Ki67) were analyzed.
Why This Research Matters
Glioblastoma is one of the most lethal brain cancers with very limited treatment options. This is described as the first preclinical evidence that CBD pretreatment before tumor establishment could inhibit progression, introducing a novel preventive concept.
The Bigger Picture
This introduces the concept of CBD as immune-modulatory preconditioning rather than treatment of existing tumors. If validated, it could represent a paradigm shift in thinking about cannabinoids and cancer prevention.
What This Study Doesn't Tell Us
Mouse model with implanted tumor cells does not replicate how glioblastoma naturally develops. CBD was administered before tumor existed, which is not a realistic clinical scenario for most patients. Small animal study requires extensive validation.
Questions This Raises
- ?Could CBD pretreatment work in humans at high risk for glioblastoma recurrence after surgical resection?
- ?What is the mechanism by which CBD preconditions the tumor microenvironment?
- ?Does the route of administration (inhaled vs. oral) matter?
Trust & Context
- Key Stat:
- 14-day CBD pretreatment significantly reduced glioblastoma tumor burden vs. placebo and 3-day CBD
- Evidence Grade:
- Preliminary: first-of-its-kind animal study with a novel concept. Requires replication and human translation before any clinical implications.
- Study Age:
- 2026 preclinical publication testing a novel CBD pretreatment concept.
- Original Title:
- Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.
- Published In:
- International journal of molecular sciences, 27(2) (2026)
- Authors:
- Wang, Lei P(3), Bhandari, Bidhan(3), Naeini, Sahar Emami(2), Hill, Breanna, Rogers, Hannah M, Gouron, Jules, Perez-Morales, Nayeli, Khan, Aruba, Meeks, William, El-Marakby, Ahmed, Young, Nancy, Vale, Fernando L, Ali, Salman, Wallace, Gerald, Yu, Jack C, Arbab, Ali S, Salles, Évila Lopes, Baban, Babak
- Database ID:
- RTHC-08699
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could CBD prevent brain cancer?
In this mouse study, CBD pretreatment before tumor implantation reduced glioblastoma growth and made tumors less aggressive. This is a very early finding that needs extensive further research before any human implications.
Why did 14 days of pretreatment work better than 3 days?
The longer exposure appeared to more effectively precondition the immune and molecular environment against tumor growth, reducing markers of immune evasion and cell proliferation.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08699APA
Wang, Lei P; Bhandari, Bidhan; Naeini, Sahar Emami; Hill, Breanna; Rogers, Hannah M; Gouron, Jules; Perez-Morales, Nayeli; Khan, Aruba; Meeks, William; El-Marakby, Ahmed; Young, Nancy; Vale, Fernando L; Ali, Salman; Wallace, Gerald; Yu, Jack C; Arbab, Ali S; Salles, Évila Lopes; Baban, Babak. (2026). Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.. International journal of molecular sciences, 27(2). https://doi.org/10.3390/ijms27020757
MLA
Wang, Lei P, et al. "Cannabidiol as a Prophylactic Agent Against Glioblastoma Growth: A Preclinical Investigation.." International journal of molecular sciences, 2026. https://doi.org/10.3390/ijms27020757
RethinkTHC
RethinkTHC Research Database. "Cannabidiol as a Prophylactic Agent Against Glioblastoma Gro..." RTHC-08699. Retrieved from https://rethinkthc.com/research/wang-2026-cannabidiol-as-a-prophylactic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.